trending Market Intelligence /marketintelligence/en/news-insights/trending/grt64r4tytFRin8mfW0eSQ2 content esgSubNav
Log in to other products

 /


Looking for more?

Contact Us
In This List

Lilly's Emgality wins US FDA nod as 1st therapy for episodic cluster headaches

Blog

Highlighting the Top Regional Aftermarket Research Brokers by Sector Coverage

Video

COVID-19 Impact & Recovery: Healthcare Outlook for H2 2021

Blog

Corporate Credit Risk Trends in Developing Markets: A Loss Given Default (LGD) Perspective

Blog

Corporate Credit Risk Trends in Developing Markets: A Probability of Default Perspective


Lilly's Emgality wins US FDA nod as 1st therapy for episodic cluster headaches

The U.S. Food and Drug Administration approved Eli Lilly and Co.'s Emgality as the first drug for treating episodic cluster headaches in adults.

Cluster headaches are recurrent attacks of severe headaches on one side of the head, frequently associated with pain behind or around one eye, restlessness and agitation. The attacks typically last 15 to 180 minutes and can occur many times a day during a cluster period.

Emgality, or galcanezumab, is an under-the-skin injection that can be self-administered once a month.

The FDA's approval for Emgality is based on a phase 3 study, which showed that the drug helped reduce weekly episodes of cluster headaches.

Emgality is already approved for preventing migraine in adults. The U.S. FDA granted a breakthrough-therapy designation to Emgality in September 2018 and a priority review status in March 2019.